BUCHAREST, Romania, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced it has entered into an exclusive distribution agreement with Danish Company Ascendis Pharma A/S (NASDAQ:ASND) for its endocrinology portfolio. Under the agreement, Er-Kim is appointed as the exclusive Ascendis A/S endocrinology distributor in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Estonia, Greece, Hungary ...

DUBAI, United Arab Emirates, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vector Pharma FZCO (Vector) today announced that it has entered into an exclusive distribution agreement with Danish company Ascendis Pharma A/S (NASDAQ:ASND) to commercialize both Skytrofa™ and Yorvipath™ in the Gulf Cooperation Council (GCC) countries of Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain. Under the terms of this exclusive distribution agreement, Vector will employ its sales and marketing expertise to distribut ...

Strategic roadmap to achieve blockbuster status for multiple products and expand the Company's engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference. "With unwavering focus on our values of Patients, Sci ...

Agreement between Ascendis Pharma A/S and ST is for the exclusive distribution and commercialisation of three Ascendis Pharma endocrinology therapies Two of the therapies are already internationally approved, the third is in development following successful Phase 2 data ST's exclusive distribution agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand and Vietnam SINGAPORE, Jan. 7, 2024 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) ...

Ascendis Pharma A/S (ASND) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Timothy Lee - Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vice President and Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Joseph Schwartz - Leerink Partners Yaron Werber - TD Cowen Li Watsek - Cantor Fitzgerald Leland Gershell - Oppenheimer Operator Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings C ...

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vice President and Chief Financial Officer Conference Call Participants Li Watsek - Cantor Paul Choi - Goldman Sachs Andreas Argyrides - Wedbush Securities David Lebovitz - Citi Leland Gershell - Oppenheimer Operator Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Confer ...

Exhibit1.1 REF. 72543-500 26June2023 ArticlesofAssociation of AscendisPharmaA /S (CVR-nr. 29918791) (Registrationno29918791) Name, Registered Office and Objects of the Company: Article 1 The company's name is Ascendis Pharma A/S. Article 2 [Deleted by resolution of the shareholders on 23 April 2015] Article 3 The object of the company is to develop ideas and preparations for the combating of disease medically, to manufacture and sell such preparations or ideas, to own shares of companies with the same objec ...

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Conference Call April 27, 2023 4:30 PM ET Company Participants Tim Lee – Senior Director of Investor Relations Jan Mikkelsen – President and Chief Executive Officer Scott Smith – Executive Vice President and Chief Financial Officer Joe Kelly – Senior Vice President, Head of Commercial Endocrinology Mads Bodenhoff – Senior Vice President, Head of Finance Conference Call Participants Jessica Fye – JP Morgan Tazeen Ahmad – Bank of America David Lebovitz – Citi Paul ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission File Number: 001-36815 Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) Tuborg Boulevard 12 DK-2900 Hellerup Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of ...

Ascendis Pharma A/S (ASND) Q4 2022 Results Conference Call February 16, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director of Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vice President, Chief Financial Officer Stina Singel - Executive Vice President, Head of Clinical Development Oncology Joe Kelly - Senior Vice President, Head of U.S. Commercial Endocrinology Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Da ...